John Lauriello

Even brief interruptions in treatment can significantly increase a schizophrenia patient's risk of psychotic relapse. Read this Academic Highlights to discover the complex factors that can contribute to treatment...

 

 

Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.

 

In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.

 

Read the recommendations of experts on the use of long-acting injectable antipsychotic medications in patients with schizophrenia.

 

You can help your patients with schizophrenia achieve the ultimate goal of treatment—recovery. Learn how to use patient-centered care to enhance medication adherence and aid functional recovery.

What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing a major contributor to relapse—nonadherence to antipsychotics.

Relapse of schizophrenia often occurs due to treatment nonadherence. Long-acting injectable (LAI) antipsychotics can improve adherence but are underused. Watch this Webcast to hear interviews with patients and learn...

Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify...